Skip to main content
Premium Trial:

Request an Annual Quote

Visible Genetics Pockets $22M in Private Share Placement

NEW YORK, Dec. 26 - Visible Genetics has secured $22 million in a private placement of some 2.6 million common shares, the company said on Wednesday. The funds will be used for general working capital purposes, Visible Genetics said.


The per-share price of $8.34 represents a 16-percent discount to the average closing price over ten days leading up to the offering.


Last month, Visible Genetics, based in Toronto, blamed a dip in sales and services on a slight decrease in third-quarter revenues, which slipped to $2.9 million from $3.0 million in the year-ago quarter. Expenses in the quarter, however, rose to $12.6 million from $10.3 million year over year.


Also for that period, the company posted net losses attributable to common shareholders of $12.6 million, or 76 cents a share, compared net losses of $9.7 million, or 63 cents a share, reported in the same period one year ago.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.